▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #539 by analyst upside · 2026-08-14
ATHE
Alterity Therapeutics Limited
Healthcare · Market Cap $85M · P/E 0x
ANALYST PRICE TARGET
+169.5%
implied upside to consensus target
Current Price $4.7
Consensus Target $12.67
Bull Target $16.0
Bear Target $10.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
0
Sell
0
52-Week Low $2.66
52-Week High $5.89
YTD Return +48.7%
FUNDAMENTALS
Market Cap $85M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $7M
Profit Margin -219.9%
52-WEEK RANGE
52-Week Low $2.66
52-Week High $5.89
Current Price $4.7
Bear Target $10.0
Bull Target $16.0
● Now $4.7 ● Target $12.67
TRADING DATA
Avg Volume 45K
YTD Return +48.7%
Analyst Count 3
Consensus Buy
Upside to Target +169.5%
Last Updated 2026-08-14

ANALYST SUMMARY

Alterity Therapeutics Limited (ATHE) is currently trading at $4.7 with a Wall Street consensus price target of $12.67, implying potential upside of 169.5% over the next 12 months. 3 analysts currently cover ATHE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $10.0.

ATHE operates in the Healthcare sector with a market capitalisation of $85M. The stock is up 48.7% year-to-date and is currently trading near the upper end of its 52-week range of $2.66 – $5.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SPRO +222.6%
Spero Therapeutics, Inc.
$72M · P/E 4.4x · Hold
BSEM +125.8%
BioStem Technologies, Inc.
$55M · P/E 3.5x · Buy
DXR +116.3%
Daxor Corporation
$61M · P/E 6.3x · Strong Buy
CCLD +150.0%
CareCloud, Inc.
$104M · P/E 35.0x · Buy
WW +96.1%
WW International, Inc.
$144M · P/E 1.6x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for ATHE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity ● Initiated
Speculative Buy 2025-12-17 Building track record
Maxim Group - Reiterated
Buy → Buy 2025-01-30 28% win rate (40 calls)
Maxim Group ● Initiated
Buy 2024-12-12 28% win rate (40 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
11/30
Consensus clarity
4/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →